Cochlear Limited

ASX:COH Stock Report

Market Cap: AU$6.2b

Cochlear Future Growth

Future criteria checks 1/6

Cochlear is forecast to grow earnings and revenue by 8.1% and 4.5% per annum respectively. EPS is expected to grow by 7.8% per annum. Return on equity is forecast to be 19% in 3 years.

Key information

8.1%

Earnings growth rate

7.75%

EPS growth rate

Medical Equipment earnings growth14.9%
Revenue growth rate4.5%
Future return on equity19.02%
Analyst coverage

Good

Last updated18 May 2026

Recent future growth updates

Analysis Article Aug 16

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Cochlear Limited ( ASX:COH ) shareholders are probably feeling a little disappointed, since its shares fell 5.4% to...

Recent updates

Narrative Update May 09

COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds

The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.
New Narrative May 09

Cochlear’s Crossroads: Temporary Setback or Structural Shift?

Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.
Narrative Update Apr 21

COH: VA Access Expansion Will Support Future Upside Despite Slight Model Adjustments

The Analyst Price Target for Cochlear has been adjusted slightly lower to A$239.95 from A$244.58, as analysts now factor in modestly softer revenue growth, profit margin and future P/E assumptions, along with a slightly higher discount rate. Valuation Changes Fair Value: adjusted slightly lower from A$244.58 to A$239.95.
Narrative Update Apr 04

COH: VA Access Expansion And Upgraded Coverage Will Underpin Future Upside

Analysts have slightly adjusted their price target for Cochlear to A$244.58 from A$245.91. This reflects updated assumptions around discount rates and valuation multiples, while core growth and profitability expectations remain broadly unchanged.
Narrative Update Mar 21

COH: VA Access Expansion Will Support Future Upside Potential

Analysts have adjusted their price target on Cochlear slightly lower to A$245.91 from A$250.59, reflecting modest tweaks to assumptions around the discount rate, revenue growth, profit margins and future P/E following recent research updates. Analyst Commentary Bullish Takeaways Bullish analysts see the revised A$245.91 target as still supportive of upside potential relative to recent trading levels, suggesting the core earnings story remains intact despite the small adjustment.
Narrative Update Mar 06

COH: Steady Assumptions And New Access Channels Will Support Future Upside Potential

Analysts have reaffirmed their A$250.59 price target for Cochlear, citing recent research that supports steady assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research behind the reaffirmed A$250.59 price target highlights a mix of supportive factors and watchpoints that matter for Cochlear's valuation and execution risk.
New Narrative Mar 01

Cloud And R&D Investment Will Pressure Margins While Long Term Hearing Demand Supports Stability

Catalysts About Cochlear Cochlear develops and manufactures hearing implant systems for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?
Narrative Update Feb 20

COH: Reset Expectations And Product Adoption Will Support Future Upside Potential

Analysts have trimmed their Cochlear price target from A$301.76 to A$250.59 as they factor in slightly lower revenue growth assumptions, a marginally higher discount rate, modestly softer profit margin expectations and a reduced future P/E multiple, as highlighted in recent Street research, including the latest upgrade at RBC Capital. Analyst Commentary Recent Street commentary around Cochlear focuses on how current expectations stack up against its A$250.59 target price and what needs to go right, or wrong, for that valuation to hold.
Analysis Article Feb 16

Cochlear (ASX:COH) Has Affirmed Its Dividend Of A$2.15

Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of April. This means...
Analysis Article Feb 15

Some Confidence Is Lacking In Cochlear Limited (ASX:COH) As Shares Slide 26%

Cochlear Limited ( ASX:COH ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
New Narrative Feb 13

Hearing Health Tailwinds And Cloud Capabilities Will Support Multi Year Earnings Expansion

Catalysts About Cochlear Cochlear develops and manufactures implantable hearing solutions for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?
Analysis Article Feb 06

Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Narrative Update Feb 05

COH: Execution Upside And Premium P/E Will Underpin Future Upside Potential

Analysts have trimmed their price target on Cochlear to about A$302 from roughly A$305, reflecting a slightly higher discount rate, modestly lower revenue growth assumptions, and a small uplift in expected profit margins and future P/E multiples. Analyst Commentary Recent research adjustments on Cochlear point to a generally constructive stance, with the trimmed price target tied to updated assumptions rather than a material change in the long term story.
Analysis Article Jan 11

Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analysis Article Nov 18

Risks To Shareholder Returns Are Elevated At These Prices For Cochlear Limited (ASX:COH)

When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 21x, you may consider...
Analysis Article Oct 14

Does Cochlear (ASX:COH) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article Sep 28

We Think Cochlear (ASX:COH) Might Have The DNA Of A Multi-Bagger

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Narrative Update Sep 19

Aging Population Will Spur Cochlear Implant Adoption Worldwide

Cochlear’s modestly lower consensus price target predominantly reflects a slight reduction in forecast revenue growth, resulting in a revised fair value estimate of A$305.38. What's in the News Cochlear extended its share buyback plan duration to August 28, 2026.
Analysis Article Aug 26

Cochlear (ASX:COH) Is Due To Pay A Dividend Of A$2.15

Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of October. This...
Narrative Update Aug 19

New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects

Cochlear’s consensus price target has been revised upward, primarily reflecting improved revenue growth forecasts and a slight increase in net profit margin, resulting in a new fair value estimate of A$309.91. What's in the News FDA approved Cochlear’s Nucleus Nexa System, the first smart cochlear implant system with upgradeable firmware, allowing recipients to access future innovations through both the implant and sound processor.
Analysis Article Jul 16

Cochlear Limited's (ASX:COH) Shares May Have Run Too Fast Too Soon

When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 18x, you may consider...
Analysis Article Jun 13

Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article May 26

Why You Should Care About Cochlear's (ASX:COH) Strong Returns On Capital

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
Analysis Article Apr 05

Unpleasant Surprises Could Be In Store For Cochlear Limited's (ASX:COH) Shares

Cochlear Limited's ( ASX:COH ) price-to-earnings (or "P/E") ratio of 46.1x might make it look like a strong sell right...
Analysis Article Mar 06

Cochlear (ASX:COH) Will Pay A Larger Dividend Than Last Year At A$2.15

Cochlear Limited's ( ASX:COH ) dividend will be increasing from last year's payment of the same period to A$2.15 on...
Analysis Article Feb 23

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
User avatar
New Narrative Feb 23

New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects

Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.
Analysis Article Feb 08

Is Cochlear Limited (ASX:COH) Worth AU$310 Based On Its Intrinsic Value?

Key Insights The projected fair value for Cochlear is AU$247 based on 2 Stage Free Cash Flow to Equity Current share...
Analysis Article Dec 20

Earnings Not Telling The Story For Cochlear Limited (ASX:COH)

Cochlear Limited's ( ASX:COH ) price-to-earnings (or "P/E") ratio of 53x might make it look like a strong sell right...
Analysis Article Nov 19

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...
Analysis Article Nov 04

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Key Insights The projected fair value for Cochlear is AU$234 based on 2 Stage Free Cash Flow to Equity Cochlear's...
Analysis Article Oct 18

We Think Shareholders May Consider Being More Generous With Cochlear Limited's (ASX:COH) CEO Compensation Package

Key Insights Cochlear's Annual General Meeting to take place on 25th of October Total pay for CEO Dig Howitt includes...
Analysis Article Sep 19

Cochlear Limited's (ASX:COH) Shareholders Might Be Looking For Exit

When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 19x, you may consider...
Analysis Article Aug 16

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Cochlear Limited ( ASX:COH ) shareholders are probably feeling a little disappointed, since its shares fell 5.4% to...
Analysis Article Aug 01

Investors Could Be Concerned With Cochlear's (ASX:COH) Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...
Analysis Article Jun 08

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Analysis Article Mar 27

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article Feb 21

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Analysis Article Dec 18

Cochlear (ASX:COH) Might Be Having Difficulty Using Its Capital Effectively

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want to...
Analysis Article Oct 04

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Key Insights The projected fair value for Cochlear is AU$192 based on 2 Stage Free Cash Flow to Equity Current share...
Analysis Article Sep 12

Cochlear (ASX:COH) Could Be Struggling To Allocate Capital

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...

Earnings and Revenue Growth Forecasts

ASX:COH - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20282,59137937048014
6/30/20272,42032732243415
6/30/20262,32625225037115
12/31/20252,339345166265N/A
9/30/20252,341367150251N/A
6/30/20252,343389135238N/A
3/31/20252,326380193290N/A
12/31/20242,309371251342N/A
9/30/20242,272364275365N/A
6/30/20242,236357299389N/A
3/31/20242,193354317410N/A
12/31/20232,149350335430N/A
9/30/20232,043326301396N/A
6/30/20231,936301267362N/A
3/31/20231,824281263352N/A
12/31/20221,713261259341N/A
9/30/20221,681275279359N/A
6/30/20221,648289299377N/A
3/31/20221,612273266340N/A
12/31/20211,575257233304N/A
9/30/20211,536291216285N/A
6/30/20211,498324199265N/A
3/31/20211,40382-5234N/A
12/31/20201,308-160-302-198N/A
9/30/20201,314-199-295-178N/A
6/30/20201,321-238-288-158N/A
3/31/20201,40034-8050N/A
12/31/20191,479306128259N/A
9/30/20191,453291N/A277N/A
6/30/20191,427277N/A296N/A
3/31/20191,422270N/A313N/A
12/31/20181,418264N/A330N/A
9/30/20181,391255N/A294N/A
6/30/20181,364246N/A258N/A
3/31/20181,329234N/A254N/A
12/31/20171,294223N/A250N/A
9/30/20171,274223N/A255N/A
6/30/20171,254224N/A260N/A
3/31/20171,218215N/A237N/A
12/31/20161,182206N/A214N/A
9/30/20161,156198N/A199N/A
6/30/20161,131189N/A185N/A
3/31/20161,088179N/A179N/A
12/31/20151,045168N/A172N/A
9/30/2015986157N/A181N/A
6/30/2015926146N/A189N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COH's forecast earnings growth (8.1% per year) is above the savings rate (3.6%).

Earnings vs Market: COH's earnings (8.1% per year) are forecast to grow slower than the Australian market (11.9% per year).

High Growth Earnings: COH's earnings are forecast to grow, but not significantly.

Revenue vs Market: COH's revenue (4.5% per year) is forecast to grow slower than the Australian market (6.2% per year).

High Growth Revenue: COH's revenue (4.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: COH's Return on Equity is forecast to be low in 3 years time (19%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/19 23:12
End of Day Share Price 2026/05/19 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cochlear Limited is covered by 26 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saul HadassinBarrenjoey Markets Pty Limited
Stuart RobertsBell Potter
Elisabeth Decou CliveBernstein